Immunome, Inc. /
Zentalis Pharmaceuticals, Inc.
Immunome purchases assets from Zentalis Pharmaceuticals
What happened
Immunome, Inc. purchased assets from Zentalis Pharmaceuticals, Inc. under an agreement with Zentalis Pharmaceuticals, Inc. and its wholly owned subsidiary, Zeno Management, Inc. The purchase transferred intellectual property and related rights to Immunome.
Immunome issued 1,805,502 shares of common stock as partial consideration. It also must pay $5,000,000 if a developmental milestone is achieved.
The source
Everything on this page comes from the source below.
Immunome purchases assets from Zentalis Pharmaceuticals
This document is the source for the companies, stage and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly